Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|TAS-117||TAS117|TAS 117||Akt Inhibitor (Pan) 21||TAS-117 is a selective allosteric inhibitor of Akt that inhibits Akt phosphorylation and downstream signaling, potentially leading to cytoxicity in tumor cells and decreased tumor growth (PMID: 24934808).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PIK3CA H1047R||breast cancer||predicted - sensitive||TAS-117||Case Reports/Case Series||Actionable||In a Phase II trial, TAS-117 treatment in a breast cancer patient harboring PIK3CA H1047R led to initial stable disease, however, disease progression was observed at 12 weeks after treatment along with an increase of non-target lesions, following which treatment was discontinued (PMID: 33723724; NCT03017521).||33723724|
|PIK3CA act mut||Advanced Solid Tumor||no benefit||TAS-117||Phase II||Actionable||In a Phase II trial, TAS-117 treatment in advanced solid tumor patients with PIK3CA activating mutations (n=12) or AKT1 E17K (n=1) refractory to standard treatment had minimal activity, and led to an overall response rate of 8% (1/13), disease control rate of 23% (3/13), median progression-free survival of 1.4 months (mo), and a median overall survival of 4.8 mo, however due to poor accrual and lack of durable response to TAS-117 early termination of study was recommended (PMID: 33723724; NCT03017521).||33723724|
|PIK3CA E545K||ovarian cancer||predicted - sensitive||TAS-117||Case Reports/Case Series||Actionable||In a Phase II trial, TAS-117 treatment in an ovarian cancer patient harboring PIK3CA E545K led to a partial response at 6 weeks after treatment and a 39% decrease in tumor size, but subsequently progression was observed at 12 weeks in non-target lesions and an increase in tumor markers at 18 weeks, and TAS-117 treatment was discontinued (PMID: 33723724; NCT03017521).||33723724|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04770246||Phase II||TAS-117||TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations||Recruiting||USA | FRA | AUT||1|